The Readout Loud
Podcast tekijän mukaan STAT - Torstaisin
350 Jaksot
-
248: The next CRISPR fight, cheaper insulin, & an FDA shuffle
Julkaistiin: 2.3.2023 -
247: Vertex vs. insurers, Moderna's future, & biotech's long winter
Julkaistiin: 23.2.2023 -
246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid
Julkaistiin: 16.2.2023 -
245: The return of bird flu and the effects of pandemic fatigue
Julkaistiin: 9.2.2023 -
244: Pharma blockbusters, pandemic policy, & legal chicanery
Julkaistiin: 2.2.2023 -
243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection
Julkaistiin: 26.1.2023 -
242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score
Julkaistiin: 19.1.2023 -
241: #JPM23 in review, the year ahead, & the merits of Miami
Julkaistiin: 12.1.2023 -
240: #JPM23, the future of Alzheimer's, & rising Covid variants
Julkaistiin: 5.1.2023 -
239: 2022 in review, CEO indictments, & the year ahead
Julkaistiin: 22.12.2022 -
238: Leaky health data, ASH22, & what it takes to get booed by your peers
Julkaistiin: 15.12.2022 -
237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing
Julkaistiin: 8.12.2022 -
236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval
Julkaistiin: 1.12.2022 -
235: LIVE from the STAT Summit
Julkaistiin: 17.11.2022 -
234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy
Julkaistiin: 10.11.2022 -
233: How the biotech revolution could come apart at the seams
Julkaistiin: 3.11.2022 -
232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
Julkaistiin: 27.10.2022 -
231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market
Julkaistiin: 20.10.2022 -
230: BIO's messy transition, mRNA's future, & Biogen's next CEO
Julkaistiin: 13.10.2022 -
229: Nobels for science, biotech dealmaking, & a friendly FTC
Julkaistiin: 6.10.2022
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.